Coronavirus disease 2019 (COVID-19) has placed an enormous strain on the health care systems of the nations where it has spread widely, with specific implications of the disease on practice in the catheterization laboratory. These implications include how we might modify practice for standard cardiac patients, those who are suspected to have COVID-19, and those with COVID-19 who have either unrelated cardiac conditions or cardiac manifestations of the disease. It merits emphasis that this is a dynamic situation and one for which there are limited data. In addition, local conditions may vary considerably. The purpose of this joint statement from the American College of Cardiology (ACC) Interventional Council and the Society for Cardiovascular Angiography and Interventions (SCAI) is to discuss issues facing catheterization laboratory personnel during this time.

Although this is new territory for most of us, it should be noted that the Middle East respiratory syndrome and severe acute respiratory syndrome epidemics within the past 2 decades did provide some limited information on the effects of highly contagious and morbid respiratory diseases on the catheterization laboratory ([@bib1]).

Patient Selection for the Catheterization Laboratory {#sec1}
====================================================

Elective patients {#sec1.1}
-----------------

Many institutions in the United States have already placed a moratorium on elective procedures within the catheterization laboratory in an effort to preserve resources and avoid exposure of patients to the hospital environment, where COVID-19 may be more prevalent. This certainly seems prudent in locales where the disease is highly prevalent. Under any circumstance, to preserve hospital bed capacity, it would seem reasonable to avoid elective procedures on patients with significant comorbidities or in whom the expected length of stay is \>1 to 2 days (or anticipated to require the intensive care unit). In addition, the definition of truly elective requires clinical judgment, because in some cases deferral of patients may have independent deleterious effects. However, examples of procedures to defer include: 1) percutaneous coronary intervention for stable ischemic heart disease; 2) endovascular intervention for iliofemoral disease in patients with claudication; and 3) patent foramen ovale closure. Case decisions should be individualized, taking into account the risk for COVID-19 exposure versus the risk for delay in diagnosis or therapy.

Patients with ST-segment elevation myocardial infarction {#sec1.2}
--------------------------------------------------------

A recent report from China outlines a protocol that relies on rapid nucleic acid testing and reliance on fibrinolytic therapy ([@bib2]). This is a controversial subject, especially in the United States, where primary percutaneous coronary intervention is the routine for patients with ST-segment elevation myocardial infarction (STEMI). Furthermore, it is complicated by the fact that access to rapid testing is limited. However, in a patient with known COVID-19 and STEMI, the balance of staff exposure and patient benefit will need to be weighed carefully. Fibrinolysis can be considered an option for a relatively stable patient with STEMI with active COVID-19. In patients with active COVID-19 in whom primary percutaneous coronary intervention is to be performed, appropriate personal protective equipment (PPE) should be worn, including gown, gloves, goggles (or shields), and an N95 mask, especially given the limited ability to take a history from such patients as well as the potential for clinical deterioration in those with STEMI. The use of powered air-purifying respirator systems may also be reasonable, especially for patients who may be vomiting (e.g., inferior STEMI) or those who may require cardiopulmonary resuscitation (CPR) and/or intubation. Importantly, the vast number of catheterization laboratories have either normal or positive ventilation systems and are not designed for infection isolation. Therefore, catheterization laboratories will require a terminal clean following the procedure, leading to delays for subsequent procedures.

Patients with NON--ST-segment elevation myocardial infarction {#sec1.3}
-------------------------------------------------------------

For most patients with non-ST-segment elevation myocardial infarction (NSTEMI) and suspected COVID-19, timing should allow for diagnostic testing for COVID-19 prior to cardiac catheterization and for a more informed decision regarding infection control. Rapid discharge of patients with primary NSTEMI following revascularization will likely be important in terms of maximizing bed availability and reducing patient exposure within the hospital. Follow-up through telehealth venues could be satisfactory in most cases. It has been suggested that in appropriately selected cases of patients with known COVID-19 and NSTEMI (e.g., particularly for those with type 2 myocardial infarction), conservative therapy may be sufficient on the basis of patient risk. It is important to note that recent reports suggest that acute cardiac injury is present in about 7% of patients with COVID-19 and may represent either type 2 myocardial infarction or myocarditis ([@bib3]). All of these factors need to be taken into account when weighing risks and benefits vis-à-vis infection control. Efforts should be made to try to differentiate between these type 2 myocardial infarctions and "primary" acute coronary syndromes, with consideration of deferral of invasive management in the former, especially if the patient is hemodynamically stable. Unstable patients with NSTEMI whose instability is due to the acute coronary syndrome (rather than other factors) may be considered under the STEMI rubric outlined earlier.

Patients requiring intubation, suctioning, or CPR {#sec1.4}
-------------------------------------------------

Intubation, suction, and active CPR likely result in aerosolization of respiratory secretions increasing likelihood of exposure to personnel. Patients who are already intubated pose less of a transmission risk to staff members given that their ventilation is managed through a closed circuit. Patients with COVID-19 or suspected COVID-19 requiring intubation should be intubated prior to arrival to the catheterization laboratory. Furthermore, the threshold to consider intubation in a patient with borderline respiratory status may need to be lowered to avoid emergent intubation in the catheterization laboratory. Some institutions have suggested using a high-efficiency particulate air filter between tube and bag if staff members are bagging an intubated patient, as bag ventilation can increase aerosolization. Other considerations are to use closed-circuit bilevel positive airway pressure machines if intubation not available. Close coordination with critical care, infectious disease, and anesthesia teams in airway management will be critical to avoid spread of infection.

Resource Allocation and Protection of the Team of Health Care Workers {#sec2}
=====================================================================

Catheterization laboratory time {#sec2.1}
-------------------------------

Consideration should be given to laboratory downsizing case volumes (e.g., deferral of elective cases) and or shift-based allocation of staff members and physicians needed to operate the laboratory in anticipation of likely disruptions to staffing. Despite measures to reduce exposure, staff shortages should be anticipated on the basis of both the possibility of infected, exposed, or quarantined staff members as well as the derivative impact on staff members due to school closings, which will put a strain on home, dependent, and child care resources. Specific consideration to subspecialty care teams may be required, with separation of persons with overlapping skill sets (e.g., avoidance of 2 structural heart interventionalists being in the same care area simultaneously). Given the infectious risk of transporting patients from wards to the catheterization laboratory, some procedures routinely done in the catheterization laboratory should be considered for bedside performance. Examples include pulmonary artery catheter placement, pericardiocentesis, and intra-aortic balloon pump insertion. As mentioned earlier, the vast majority of catheterization laboratories have either normal or positive ventilation systems and are not designed for infection isolation. Given the need for terminal cleaning following procedures on patients with suspected or known COVID-19, these cases should be done at the end of the working day if possible. For known COVID-19-positive patients, restriction of cases to a dedicated laboratory may be of value.

Protection of Health Care Workers and PPE {#sec3}
=========================================

All catheterization laboratory personnel should be fit-tested for N95 masks and be well versed in the proper techniques for doffing and donning PPE, including eye protection. There may be situations in which the use of powered air-purifying respirator systems is advised. All catheterization laboratory directors and managers should work closely with their institutional infection control groups to ensure adequate availability and training in the use of this equipment. Ideally for patients with known COVID-19 or suspected COVID-19 who are required to come to the catheterization laboratory, patients should wear surgical masks, and all members of the catheterization laboratory team should don PPE (preferably for aerosolized precautions given the risk of emergent intubation, suctioning, and CPR).

In addition to the known shortage of N95 masks, there are emerging reports of shortages of gowns, gloves, and regular surgical masks. This supports the deferral of elective cases and a reduction in the number of people who scrub into procedures. This is particularly relevant for teaching institutions, at which multiple physicians often scrub into cases. Vendor access and use of PPE should be limited to those cases only when absolutely essential.

A Need for Ongoing Information {#sec4}
==============================

As the medical community gains more experience dealing with the various issues raised by the COVID-19 pandemic, it will be important to have an ability to exchange experiences and best practices. Already, social media has provided a venue for some excellent discussions and insight from practitioners at institutions experiencing the effects of the pandemic. As the pandemic progresses, we will need to create avenues for reporting and collation of data and then methods for rapidly dispersing that information in order to better care for our patients and to protect health care workers.
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